Unlocking the UK’s virtual drug discovery capability
The UK is well positioned to take advantage of virtual drug discovery services, says Medicines Discovery Catapult’s Graeme Wilkinson
Read More
Tag: Medicines Discovery Catapult; virtual drug discovery; R&D
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
